Date | Price Target | Rating | Analyst |
---|---|---|---|
1/29/2024 | $23.00 → $9.00 | Overweight → Neutral | JP Morgan |
9/8/2023 | $23.00 → $14.00 | Buy → Neutral | BofA Securities |
3/6/2023 | $35.00 → $34.00 | Neutral → Overweight | JP Morgan |
2/21/2023 | $41.00 → $53.00 | Neutral → Buy | Goldman |
1/27/2023 | $18.00 → $30.00 | Underweight → Equal-Weight | Morgan Stanley |
9/14/2022 | $40.00 | Outperform | SVB Leerink |
9/9/2022 | $15.00 | Underweight | Morgan Stanley |
3/3/2022 | $36.00 → $28.00 | Underperform → Neutral | Baird |
8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
10-Q - Vir Biotechnology, Inc. (0001706431) (Filer)
8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
– Seasoned biotech executive brings decades of effective financial leadership to Vir – Vir Biotechnology Inc. (NASDAQ:VIR) today announced that Jason O'Byrne, MBA, is appointed as Executive Vice President and Chief Financial Officer (CFO), effective October 2, 2024. Mr. O'Byrne will join the Vir Executive Management Team and report directly to the company's Chief Executive Officer, Marianne De Backer, M.Sc., Ph.D., MBA. Mr. O'Byrne is an accomplished executive with more than 20 years of experience in finance and operations. He is a recognized champion of financial discipline and brings demonstrated financial leadership in capital allocation and formation, corporate strategy, and operation
– License of proprietary masking platform further strengthens Vir's drug discovery capabilities in oncology and infectious disease – – Strategic agreement expands Vir portfolio with three clinical stage assets in areas of high unmet need – Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the exclusive worldwide license agreement with Sanofi announced on August 1, 2024, has closed following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The agreement provides Vir with an exclusive worldwide license to three clinical-stage masked T-cell engagers (TCEs) with potential applications in a range of cancers and exclusive use of the propri
Vir Biotechnology Inc. (NASDAQ:VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, at 1:50 p.m. PT / 4:50 p.m. ET in New York City. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days. About Vir Biotechnology, Inc. Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application and granted Fast Track designation for the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta infection. Tobevibart, an investigational monoclonal antibody, and elebsiran, an investigational small interfering ribonucleic acid, are currently being evaluated in the Company's Phase 2 SOLSTICE hepatitis delta clinical trial, with complete 24-week treatment data on track to be reported in the fourth quarter.
Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Equal-Weight and raises the price target from $12 to $15.
On Wednesday, Vir Biotechnology Inc (NASDAQ:VIR) announced new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating tobevibart and elebsiran for chronic hepatitis delta. Preliminary data from the Phase 2 trial show that treatment with tobevibart alone or combined with elebsiran was generally well tolerated. Participants achieved high virologic response rates at weeks 12 and 24, durable virologic response through 48 weeks, and high alanine transaminase (ALT) normalization rates. High levels of alanine aminotransferase (ALT) within a range of 1000-2000 IU/mL, is the hallmark of this stage of HBV disease. Similar virologic suppression and ALT normaliz
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
JP Morgan downgraded Vir Biotechnology from Overweight to Neutral and set a new price target of $9.00 from $23.00 previously
BofA Securities downgraded Vir Biotechnology from Buy to Neutral and set a new price target of $14.00 from $23.00 previously
JP Morgan upgraded Vir Biotechnology from Neutral to Overweight and set a new price target of $34.00 from $35.00 previously
– Seasoned biotech executive brings decades of effective financial leadership to Vir – Vir Biotechnology Inc. (NASDAQ:VIR) today announced that Jason O'Byrne, MBA, is appointed as Executive Vice President and Chief Financial Officer (CFO), effective October 2, 2024. Mr. O'Byrne will join the Vir Executive Management Team and report directly to the company's Chief Executive Officer, Marianne De Backer, M.Sc., Ph.D., MBA. Mr. O'Byrne is an accomplished executive with more than 20 years of experience in finance and operations. He is a recognized champion of financial discipline and brings demonstrated financial leadership in capital allocation and formation, corporate strategy, and operation
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the appointment of Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer, effective November 6, 2023. Dr. Towne will be responsible for leading the Company's research function from basic research through scale-up manufacturing and the introduction of drug candidates to clinical trials. She will report to Vir's Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will join the Company's Executive Management Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231026830042/en/Jennifer Towne, Ph.D., appointed as Executive Vice President and
SC 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)
SC 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)
SC 13G - Vir Biotechnology, Inc. (0001706431) (Subject)
– Positive preliminary Phase 2 chronic hepatitis delta study data presented at EASL™ Congress 2024, FDA IND clearance with Fast Track Designation received underscoring the potential of combination therapy – – Exclusive license agreement with Sanofi bolsters clinical pipeline – – Strategic workforce restructuring and phasing out of influenza, COVID-19, and the Company's T cell-based viral vector platform programs – – $1.43 billion in cash, cash equivalents and investments as of June 30, 2024 – – The Company lowers full-year 2024 operating expense guidance – – Conference call scheduled for August 1, 2024 at 1:30 p.m. PT / 4:30 p.m. ET – Vir Biotechnology, Inc. (NASDAQ:VIR) today p
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. Participants may access the conference call via webcast on the Events & Presentations page of Vir's website at https://investors.vir.bio/events-presentations or listen in by dialing the U.S. toll free number (800) 715-9871 or international +1 (646) 3
– Preliminary Phase 2 SOLSTICE trial data reinforce the potential of both regimens to be transformative treatments in an area of high unmet medical need – – Conference call scheduled for June 5, 2024, at 6:00 a.m. ET / 12:00 p.m. CEST – Vir Biotechnology, Inc. (NASDAQ:VIR) today announced new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating tobevibart, an investigational monoclonal antibody, and elebsiran, an investigational small interfering ribonucleic acid, for the treatment of people living with chronic hepatitis delta. Preliminary data from the Phase 2 trial show treatment with tobevibart alone or in combination with elebsiran was generally well